1. Blood Glucose Control During Lockdown for COVID-19: CGM Metrics in Italian Adults With Type 1 Diabetes
- Author
-
Brunella Capaldo, Roberta Lupoli, Lutgarda Bozzetto, Gabriele Riccardi, Maria Masulli, Raffaele De Angelis, Angela A. Rivellese, Annalisa Creanza, Giovanni Annuzzi, Clemente Giglio, Capaldo, Brunella, Annuzzi, Giovanni, Creanza, Annalisa, Giglio, Clemente, De Angelis, Raffaele, Lupoli, Roberta, Masulli, Maria, Riccardi, Gabriele, Rivellese, Angela Albarosa, and Bozzetto, Lutgarda
- Subjects
Adult ,Blood Glucose ,Insulin pump ,Pediatrics ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Pneumonia, Viral ,030209 endocrinology & metabolism ,Betacoronavirus ,03 medical and health sciences ,0302 clinical medicine ,Diabetes and COVID-19: Tactics for Study and Management ,Informed consent ,Diabetes mellitus ,Blood Glucose Self-Monitoring ,Internal Medicine ,Humans ,Medicine ,Outpatient clinic ,Registries ,030212 general & internal medicine ,Pandemics ,Glycemic ,Advanced and Specialized Nursing ,Type 1 diabetes ,SARS-CoV-2 ,business.industry ,Insulin ,COVID-19 ,medicine.disease ,Benchmarking ,Diabetes Mellitus, Type 1 ,Italy ,Coronavirus Infections ,business - Abstract
To prevent the spread of COVID-19, lockdown was imposed in many countries with rigid restrictions on all outdoor activities, also limiting attendance at diabetes clinics. In patients with diabetes, lockdown implies lifestyle changes related to physical activity, stress, and nutrition that are likely to adversely affect glycemic control (1). Conversely, during lockdown, individuals with type 1 diabetes (T1D) are to be expected to have a more regular lifestyle, more closely respecting time schedules and insulin administration timing. We evaluated the impact of lockdown on glucose control in 207 Italian adults with T1D attending the Diabetes Outpatient Clinic of the Federico II University Hospital, Naples: 96 females/111 males, mean ± SD age 38.4 ± 12.7 years, 104 on multiple daily insulin injections (MDI), and 103 on insulin pump (continuous subcutaneous insulin infusion [CSII]). Inclusion criteria were continuous glucose monitoring (CGM) for at least 6 months, including a 2-week period with CGM use >70% before (January–February) and during (March–April 2020) lockdown, while maintaining the same device: FreeStyle ( n = 130), Guardian 3 ( n = 47), Dexcom G6 ( n = 18), and Eversense ( n = 12). Each participant gave informed consent for the use of her or his data. No participant reported …
- Published
- 2020
- Full Text
- View/download PDF